A circulating biomarker for use in monitoring metastatic breast cancer
Ended Project Grant Awarded Last action
- Award ID
- R44CA210817
- Recipient
-
A&G Pharmaceutical, Inc. UEI SN6SWFABJXL1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,214,005
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | -$99,823 | |
| Amendment | $70,818 | |
| Amendment | $0 | |
| Amendment | $141,660 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $1,101,350 |
Quick answers
Who received award R44CA210817?
R44CA210817 was awarded to A&G Pharmaceutical, Inc. by National Cancer Institute (National Institutes of Health) on August 23, 2018.
How much is award R44CA210817 worth?
$1,214,005 has been obligated on R44CA210817.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award